ClinicalTrials.gg
RecruitingNCT07846423IDNOW2026Updated Sep 29, 2026

Abbott ID NOW Point-of-Care Testing

An interventional study of Abbott ID NOW Point-of-Care Testing and Standard Laboratory-Based RT-PCR Diagnostic Pathway in Influenza and Influenza-like Illness, sponsored by China Medical University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by China Medical University Hospital · Not applicable, Interventional, and Screening

How we know

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,080
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Influenza, Human with a site in Taiwan — 6 open to participants now, 6 under way, 2 of them phase 3. Influenza, Human · Taiwan.

Planned enrollment
14th of 47
1,080 · median 300
Started
2026
with 1 other
No phase
7 of 52
2 open now
Registered
52nd of 52
by date
Lead sponsor
2 of 52
China Medical University Hospital

Among the 52 studies in Influenza, Human with a site in Taiwan, this one is the 14th largest by planned enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 with no phase, and was the 52nd registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

6 of the 52 studies in Influenza, Human with a site in Taiwan are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Influenza, Human with a site in Taiwan, or all of them as a file.
02

Study summary

With the rapid aging of the global population, long-term care facilities (LTCFs) have become an increasingly important component of modern public health systems. However, these settings are also at high risk for outbreaks of respiratory infectious diseases. Influenza virus transmission within LTCFs has distinct epidemiological characteristics, including high transmissibility and high risks of severe illness and mortality. In Taiwan, with the accelerated aging of the population, LTCF residents commonly have multiple chronic comorbidities (multimorbidity) and age-related immune dysfunction (immunosenescence). Influenza infection in this population may not only lead to acute respiratory failure but may also contribute to a "silent burden," including post-infection cardiovascular events, metabolic dysregulation, and long-term functional decline.

Under the current standard of care (SOC), influenza diagnosis relies on reverse transcription polymerase chain reaction (RT-PCR) testing performed by external laboratories, with a turnaround time (TAT) of approximately 24 to 48 hours. This time-to-result gap may delay clinical decision-making, potentially preventing timely initiation of antiviral treatment within the optimal 48-hour treatment window and leading facilities to adopt broad precautionary isolation measures, thereby increasing healthcare resource utilization and staffing burden.

The Abbott ID NOW system uses isothermal nucleic acid amplification technology (INAAT) and can provide molecular diagnostic results within approximately 15 minutes. Through a prospective cluster-randomized controlled design, this study aims to evaluate whether implementation of an ID NOW-based point-of-care testing (POCT) strategy can improve clinical outcomes among LTCF residents and reduce overall healthcare costs compared with the current standard diagnostic pathway.

Read the detailed description

Long-term care facilities (LTCFs) play an increasingly important role in healthcare systems as populations age. However, LTCFs are also settings with a high risk of respiratory infectious disease transmission. Influenza outbreaks in these facilities are of particular concern because residents often have advanced age, multiple chronic comorbidities, and age-related immune dysfunction, all of which may increase the risks of severe disease, hospitalization, and mortality. In addition to acute respiratory complications, influenza infection in this population may also be associated with subsequent cardiovascular events, metabolic deterioration, and prolonged functional decline.

In current clinical practice, influenza diagnosis in LTCFs commonly relies on reverse transcription polymerase chain reaction (RT-PCR) testing performed by external laboratories. The interval between specimen collection and reporting of results may be approximately 24 to 48 hours. This delay may affect the timing of clinical decision-making, including initiation of antiviral therapy and implementation of infection prevention and control measures. During the period when diagnostic results are unavailable, LTCFs may also need to implement precautionary isolation or cohorting measures for residents with suspected influenza-like illness, which may increase healthcare resource utilization and staff workload.

The Abbott ID NOW system is a rapid molecular diagnostic platform based on isothermal nucleic acid amplification technology (INAAT) and can provide molecular test results within approximately 15 minutes. The availability of rapid molecular testing at the point of care may shorten the time between clinical suspicion, diagnostic testing, and subsequent management decisions.

This study is designed as a prospective, cluster-randomized, open-label, two-arm, active-controlled study to evaluate the impact of two different influenza diagnostic strategies in residents of LTCFs in Taiwan: an ID NOW-based point-of-care testing strategy and the current standard diagnostic pathway. The study aims to determine whether the implementation of rapid point-of-care molecular testing can improve clinical outcomes and healthcare resource utilization compared with the standard diagnostic approach.

The study is planned to be conducted in 8 to 10 legally registered residential LTCFs, including nursing homes and other long-term care institutions, located in northern, central, southern, and eastern Taiwan. Participating facilities are required to have at least 40 approved beds, sufficient healthcare personnel to follow the study procedures, the ability to perform on-site specimen collection and infection-control measures, and an established system of regular physician visits. Institutional management approval is required before a facility enters the randomization process.

Specific participating rooms within the study facilities will be designated for study participation. Residents living in these participating rooms will be considered potential participants during the study period. Enrollment will be event-driven rather than based on routine screening of all residents. Nursing staff at participating LTCFs will monitor residents for acute clinical events suggestive of influenza-like illness. When a resident develops symptoms or signs that meet the study inclusion criteria, the responsible physician will perform a clinical assessment to determine whether the resident is potentially eligible and to exclude alternative diagnoses that clearly explain the clinical presentation. After eligibility assessment and informed consent, the resident will be formally enrolled in the study.

Eligible participants may include residents with acute onset of fever, decreased oxygen saturation, respiratory symptoms, or clinical suspicion of influenza. Specific eligibility criteria include acute illness with tympanic temperature of at least 38°C persisting for at least 24 hours; acute illness associated with decreased oxygen saturation or deterioration in oxygenation; influenza infection highly suspected by the treating physician; residents aged 65 years or older with relevant comorbidities who develop acute illness with tympanic temperature of at least 37.5°C persisting for at least 24 hours; or at least one respiratory symptom, such as cough, sore throat, or rhinorrhea, persisting for at least 24 hours.

Residents will be excluded if an alternative definite diagnosis is identified at the initial assessment that adequately explains the influenza-like illness, including conditions such as bacterial pneumonia, non-respiratory infection, aspiration pneumonia, definite urinary tract infection, or exacerbation of heart failure without evidence of infection. Additional exclusion criteria include refusal to provide informed consent, expected survival of less than 48 hours, previous participation in the study within the preceding 14 days, and residence in a dedicated dementia care unit.

In the intervention group, eligible residents with suspected influenza-like illness will undergo point-of-care molecular testing using the Abbott ID NOW system. Nasal or nasopharyngeal swab specimens will be collected at the LTCF, and the test result will be available rapidly to support subsequent clinical and infection-control decisions. In the control group, residents will be managed according to the current standard diagnostic pathway, which relies on conventional laboratory-based RT-PCR testing and routine clinical management.

The study is open-label because the diagnostic strategy assigned to each group cannot be concealed from healthcare personnel. The study uses a parallel two-group design with active comparison between the ID NOW point-of-care testing strategy and the standard diagnostic pathway.

A total of 1,080 participants are planned for enrollment. The minimum eligible age is 20 years, with no specified upper age limit. Each enrolled participant will be followed for 30 days after the qualifying influenza-like illness event.

Clinical and healthcare utilization data will be collected during the follow-up period to evaluate differences between the two diagnostic strategies. The study is intended to provide evidence on whether rapid point-of-care molecular testing can shorten the diagnostic process, support more timely clinical and infection-control decision-making, improve resident outcomes, and reduce unnecessary healthcare resource utilization and overall healthcare costs in LTCFs.

03

Conditions studied

  • Influenza
  • Influenza-like Illness

Browse trials for

Keywords

  • Point-of-Care Testing
  • Long-Term Care Facility
  • Cluster-Randomized Controlled Trial
  • Influenza-like illness
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute onset of illness with fever (tympanic temperature ≥38°C) persisting for at least 24 hours.
  • Acute onset of illness accompanied by decreased oxygen saturation (e.g., SpO₂ decreased to 94% or deterioration in oxygenation), or influenza infection highly suspected by the treating physician.
  • Residents aged 65 years or older with comorbidities (e.g., diabetes mellitus, dialysis, hypertension, heart disease, or use of agents) who develop acute illness with fever (tympanic temperature ≥37.5°C) persisting for at least 24 hours.
  • At least one respiratory symptom, such as cough, sore throat, or rhinorrhea, persisting for at least 24 hours.

Exclusion criteria

Exclusion Criteria:

  • A definite alternative diagnosis identified at the initial assessment that explains the influenza-like illness, such as bacterial pneumonia, non-respiratory infection, aspiration pneumonia following choking during feeding, definite urinary tract infection, or known exacerbation of heart failure without evidence of infection.
  • Refusal by the resident or the resident's legally authorized representative to provide for data collection.
  • Expected survival of less than 48 hours, as assessed by a physician.
  • Participation in this study within the previous 14 days, to avoid duplicate enrollment for the same illness episode.
  • Residence in a dedicated dementia care unit, because differences in disease characteristics, communication ability, and care practices may affect the internal validity of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,080 participants (estimated)

Study arms

  • Experimental
    ID NOW Point-of-Care Testing Strategy

    Participants in this arm will receive point-of-care molecular testing for suspected influenza using the Abbott ID NOW system at the participating long-term care facility. Nasal or nasopharyngeal swab specimens will be collected on site, and the rapid test result will be used to support subsequent clinical management and infection prevention and control decisions.

    Device: Abbott ID NOW Point-of-Care Testing

  • Active comparator
    Standard Diagnostic Pathway

    Participants in this arm will receive the current standard diagnostic pathway for suspected influenza, including laboratory-based reverse transcription polymerase chain reaction (RT-PCR) testing performed through the usual external laboratory process, together with routine clinical management and infection-control measures.

    Diagnostic Test: Standard Laboratory-Based RT-PCR Diagnostic Pathway

Interventions

  • DeviceAbbott ID NOW Point-of-Care Testing

    Abbott ID NOW is a rapid molecular diagnostic platform based on isothermal nucleic acid amplification technology for the detection of influenza. Testing will be performed at the participating long-term care facility using nasal or nasopharyngeal swab specimens collected from eligible residents with suspected influenza-like illness. The system can provide molecular test results within approximately 15 minutes.

  • Diagnostic testStandard Laboratory-Based RT-PCR Diagnostic Pathway

    Standard-of-care influenza testing using reverse transcription polymerase chain reaction (RT-PCR) performed through the usual external laboratory workflow. Test results are generally available within approximately 24 to 48 hours and are used together with routine clinical assessment to guide subsequent management and infection-control decisions.

06

What researchers measure

Primary outcomes

  1. Time From Specimen Collection to Availability of Influenza Test Result

    Time elapsed between collection of the respiratory specimen and availability of the influenza test result for clinical decision-making, compared between the ID NOW point-of-care testing strategy and the standard laboratory-based RT-PCR diagnostic pathway.

    Time frame: During the index influenza-like illness episode, from specimen collection to availability of the test result, up to 48 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Of 147 non-industry interventional studies with no phase under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 18. This study's planned 14 months is above that.

Counting every sponsor, half of 167 studies reached it within 6 months; a quarter within 3 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 29, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846423
Responsible party
Po-Ren Hsueh (Superintendent, China Medical University Hospital) — Principal investigator
First posted
Sep 29, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Chia-Hui Tan, Ph.D
Contact
elisetan@mail.cmu.edu.tw
886-4-2205-3366 ext. 6321

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion